



February 3, 2016

Xencor to Present at Two Upcoming Conferences in February

MONROVIA, Calif., Feb. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:

1 **Leerink Partners 5th Annual Global Healthcare Conference**

Date: Wednesday, February 10, 2016

Time: 8:50 a.m. ET

Location: New York, NY

1 **2016 RBC Capital Markets' Healthcare Conference**

Date: Wednesday, February 24, 2016

Time: 4:35 p.m. ET

Location: New York, NY

Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. Currently, nine candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871, which completed a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease in 2016; XmAb7195 in Phase 1a development for the treatment of asthma; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.

Investor Contact:

John Kuch, Vice President Finance, Xencor

Tel: 626-737-8013

jkuch@xencor.com

Corporate Communications Contact:

Jason I. Spark, Canale Communications for Xencor

Tel: 619-849-6005

jason@canalecomm.com

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/xencor-to-present-at-two-upcoming-conferences-in-february-300214031.html>

SOURCE Xencor

News Provided by Acquire Media